Business Description

Kalytera Therapeutics (TSXV: KALY) is a clinical-stage pharmaceutical company pioneering the development of a next generation of cannabinoid therapeutics. Through its proven leadership, drug development expertise, and intellectual property portfolio, Kalytera seeks to establish a leading position in the development of novel cannabinoid medicines for a range of important unmet medical needs, with an initial focus on Graft versus Host Disease (“GvHD”). Kalytera is also developing a new class of proprietary cannabidiol (“CBD”) therapeutics. CBD is a remarkable compound that has shown activity against a number of pharmacological targets. However, there are limitations associated with natural CBD, including its poor oral bioavailability. Kalytera is developing innovative CBD formulations and prodrugs in an effort to overcome these limitations, and to target specific disease sites within the body. Kalytera intends to file composition of matter and method of use patents covering its novel inventions, with the goal of limiting future competition. Learn more >>

IR Contacts

IR Contact
Robert Farrell
rfarrell@kalytera.co 
(888) 861-2008

U.S. and Canadian Legal Counsel
Torys LLP
79 Wellington Street West
Toronto, Ontario  M5K 1N2 Canada

Transfer Agent
TSX Trust
(866) 393-4891
www.tsxtrust.com

Auditor
Ernst & Young LLP
700 West Georgia Street
V7Y 1C7 Vancouver

Industry Classifications

Sector
Biotechnology

Industry
Research and Development

NAISC
541711

SIC
8731